For a better user experience please update your browser or use Chrome or Firefox browser.
Utilidades
Publication detail
HomeStudy on enhanced cross-country coordination in the area of pharmaceutical product pricing
Final report
Metadatos de publicación
European patients and citizens need access to safe, effective and affordable medicines while the health care system should be financially sustainable, and innovation should be encouraged. This is perhaps the key challenge for the national competent authorities and public payers as pharmaceutical pricing and reimbursement remains the competence of EU Member States. In the light of increasing financial pressure while further new high-priced medicines are expected to come to the market, new approaches to achieve the above-mentioned objectives might be required. Without disregarding the subsidiarity principle, possible benefits of cooperative approaches should be studied and discussed. In this context, a consortium of Gesundheit Österreich Forschungs- und Planungs GmbH, SOGETI Luxembourg S.A. and the University for Health Sciences, Medical Informatics and Technology was commissioned by the European Commission (DG SANTÉ / Chafea) to explore the pharmaceutical pricing policies of external price referencing (EPR) and differential pricing (DP) with regard to their ability to achieve two of the three above-mentioned policy objectives: to improve patients’ access to medicines and to generate savings for public payers. In particular, this ‘study on enhanced cross-country coordination in the area of pharmaceutical product pricing’ aimed to survey existing EPR schemes in European countries and to develop possible improvements to the current EPR practice, as well as to analyse how DP schemes could possibly be designed for European countries, including addressing identified constraints to DP in Europe. Furthermore, it should be explored how EU-level coordination mechanisms could support the improvement of EPR systems and the establishment of a DP scheme. To achieve these research objectives, the authors relied upon a range of methods including a literature review, a survey of competent authorities for pharmaceutical pricing, interviews with procurement experts, price simulations, a legal analysis, research of cooperation models and SWOT (strengths, weaknesses, opportunities, and threats) analyses. Extensive reviews involving the services of the EC, stakeholders and academics (‘peers’) were performed to ensure the high quality of the report.
- Publicado:
- Тemas: Industria farmacéutica y cosmética
- Tema: autorización de venta , competitividad , gastos de sanidad , gastos farmacéuticos , industria farmacéutica , legislación farmacéutica , mercado de la UE , política de precios , producto farmacéutico , regulación de precios
|
PDF
|
|||
| ISSN | ISBN 978-92-79-53462-1 | DOI 10.2875/631265 | Número de catálogo EW-01-15-894-EN-N |
- Released on EU publications website:
Visualizador de documentos
Note:
La publicación no puede mostrarse en el visualizador de documentos. Abrir la versión web
Puede acceder a ella desde: Descarga y lenguas